Introduction
Herpes labialis also called as cold sore affects the lips followed by sores, fever, sore throat or enlarged lymph nodes, etc. (symptoms). According to World Health Organisation, more than 3.7 billion people globally and 320 million people in America suffer from lip outbreaks duetto herpes simplex virus, therefore, prevalence of the disease is the major factor for growth in treatment market and more research. Technological advancements, introduction of new products by manufacturers may help in strengthening the Herpes Labialis Treatment sector during the forecast period.
The research conducted by MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials in 2020 reports the use of antiviral agents for the prevention and treatment of Herpes Simplex Virus Type -1 Infection among patients undergoing cancer treatment. A network meta-analysis was performed on the data from randomised control which assess antiviral agents for preventive activity vs placebo. The research was conducted to identify the best anti-viral agents to prevent HSV infection among patients undergoing cancer. The results demonstrated that relative risk in the acyclovir group was 0.17 compare to 0.22 in the valacyclovir.
Clear Probiotics in June 2020 launched a symbiotic to avert herpes outbreak. Also, they have launched a probiotic and prebiotic formula aiming to prevent lip outbreaks due to symptoms associated with herpes simplex virus type-1. The Clear Probiotics formulation contain Lactobacillus Rhamnosus GG which may have a beneficial implications as a co-treatment in lip outbreaks due to its antiviral components. The components such as Lactobacillus rhamnosus and fructooligosaccharides in Clear Probiotics can significantly decrease the occurrence and incidence of herpes labialis lesions after stimulation with ultraviolet radiations.
In November 2020, Amneal obtained FDA approval for acyclovir for the treatment of recurrent herpes labialis in adults and teenagers of 12 years and older. This approval is a precedent for the company as it is a first tropical cream product approved. The approval has helped the company with providing more accessible, complex generic formulations to patients and the health care system of US.
The global market for herpes labialis treatment is poised to expand at a moderate CAGR of 4.6% over 2017-2027. Up from US$ 869.3 Mn achieved in 2017, the global herpes labialis treatment market will possibly reach beyond US$ 1.3 Bn by the end of 2027.
Soaring penetration of generics and frequent transformations in disease treatment will collectively push the market up, whereas innovations in drug type and mode of action will accelerate the demand for herpes labialis treatment in near future. Apart from increasing prevalence of viral infections and rising R&D investments, mergers and acquisitions among the leading companies will also play a crucial role in uplifting the market performance.
Key Players Strongly Support North America’s Dominance
With over 35% value share, North America stood the top market for herpes labialis treatment in 2017. This region is expected to continue its dominance through the forecast period, followed by Western Europe, which recorded over 20% share of the total market value in 2017. APEJ and MEA are also slated for decent market value shares over the assessment period. The North American market is foreseen to take a moderate leap from US$ 310.3 Mn (2017) to US$ 457.1 Mn by the end of forecast period at a CAGR of 3.9%. While the US is expected to maintain dominance, Canada is presumed to witness higher growth during the 10-year period.
Increasing efforts and investments in examining clinical efficacy of drugs through research and development, frequent product innovation, and rapid development of cost-effective and advanced treatment options are identified to be the key factors strengthening the growth of North America’s market for herpes labialis treatment.
US-based Companies Lead Market, Extended Product Portfolio Remains Paramount
A majority of US-based leaders in market are concentrating on new product launches through organic and inorganic growth. While strategic collaborations are likely to provide the market with a significant thrust, expansion of existing product portfolio is likely to be the agenda for key players. As FDI policies regulating the pharmaceuticals industry within developing economies are often considered relatively more liberal, established global herpes labialis treatment market players are most likely to amplify their mark within developing regions over the forecast period.
- Pfizer Inc., one of the leading players in herpes labialis treatment market, is a New York-based company. With a flagship product - Acyclovir sodium injection, which is a pharmaceutical product used as an antiviral agent, this brand sells in two segments viz. essential health and innovative health. Acquisition of a leader in biosimilar and injectable - Hospira Inc. has helped the company to expand its portfolio in herpes injectable.
- Mylan NV, based in Canonsburg, is a leader in Valacyclovir, Acyclovir, and Famciclovir. While the company already has a diversified product portfolio including a vast range of generics and specialty products, it has recently widened its R&D infrastructure post-acquisition of Meda Pharma. Generic drug approvals seem to be a booster for several opportunities in the herpes infection treatment market. In April 2017, Mylan Pharmaceuticals (subsidiary) received US FDA’s final approval for Acyclovir Ointment USP.
- Abbott Laboratories is based in Illinois and specializes in Acyclovir Sodium – an injectable antiviral agent. With a broad portfolio serving over 150 countries, the company is currently focusing on expanding its presence in Indian, Chinese, Russian, Colombian, and a few other developing markets. Growing R&D expenditure is foreseen to aid the company in near future. The company divested its branded generics business in developed markets and retained the business in emerging markets in order to capitalize the growing emerging branded generics market.
Market Taxonomy
Dug type
- Acyclovir
- Valacyclovir
- Famciclovir
- Penciclovir
- Docosanol
Route of administration
- Topical
- Oral
Distribution channel
- Hospital pharmacies
- Retail pharmacies
- Drug stores
- Online pharmacies
Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- MEA
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports